FDA tags psilocybin drug as clinical depression Breakthrough...

The FDA has tagged psilocybin, the illegal psychoactive compound found in ‘magic mushrooms’, as a potential breakthrough treatment for major depressive disorder.

J&J seeks wider use of its Spravato antidepressant in US

J&J’s Spravato for depression ‘should be much cheaper’

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

Abilify MyCite and innovating in digital health

pharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the company’s innovative digital collaboration with Pr

FDA approves Janssen’s ketamine-based nasal antidepressant

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted

FDA panel backs J&J's potential depression blockbuster

A panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal spray for depression, esketamine, bringing the medicine closer to approval.